Join us at the CABA 2016 Annual Conference at Boston

    Good news again from Chinese-American BioMedical Association (CABA). CABA’s 2016 Annual Conference will be held concurrently with CABA’s Job Fair in Boston on April 30. It is a great opportunity for both the speech from professionals and finding the new career opportunities. Medicilon, as one of the sponsors, will set up a booth during the conference. We welcome you to attend the conference and we look forward to seeing you there.

    As CABA’s most influential event, the conference attracts hundreds of life scientists, professionals, venture capitalists, patent lawyers and highly talented students from the Greater Boston area. The conference consists of 2 parts, academic speech and job fair. There will be 10 senior executives of leading pharmaceutical companies, prominent scientists and entrepreneurs from both US and China to share their perspectives on biomedical research and business development in the current world economy. Dr. Jun Wang, Medicilon’s VP of Biology, will be there to give out a presentation on the topic of “The perspective of Pharmaceutical and CRO Industry in China”.

    “For Pharmaceutical and CRO Industry, focusing on production and innovation is certainly important, but I would say the insight of perspective needs is vital to the company’s future,” Dr. Jun Wang stated, ”The Pharmaceutical and CRO is a good and emerging industry in China. From views of opportunities for starting a business, investment, returnees job market, new Chinese regulations relating to generics and transfer of patent for new medicine in recent years, Chinese Pharmaceutical Industry is now becoming more rigorous and innovative. Chinese government paid great attention to the development of pharmaceutics and its promotion internationally. This would be a good opportunity for CRO industry. Seizing this opportunity will boost our development and pushing forward the development of pharmaceutics in China. Therefore, I am confident with the future development of pharmaceutical and CRO Industry in China”.

    As one of the top CRO companies in China, Medicilon continuously adjusts its development according to the changing of the environment.  In order to satisfy the needs of one-stop service in the market, Medicilon gradually develops the services of compound synthesis, structural biology, pharmacodynamics evaluation, pharmacokinetic and toxicological evaluation.  The one-stop service, that Medicilon provides, accredited by international drug authorities.

Meeting Agenda

Date:  9:00am-9:00pm   April 30th 2016

Location: Sanofi-Genzyme Corporation, 153 2nd Avenue, Waltham, MA 02451 Boston

About CABA

    CABA is a not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development. As the majority of its members are scientists with Chinese heritage, CABA will operate in two important areas. One is to serve as a platform for its members to develop and advance their careers in the US pharmaceutical and biomedical industry, the other is to serve as a bridge to connect members including corporate members with the scientific and business resources in China thus facilitating collaboration between the pharmaceutical and biomedical industries across continents. To fulfill these goals, we will organize scientific and business symposia, conferences, workshops, in US and China, as well as social events to promote networking and communication among members. We will bring together members, scientists, professionals, government officials and business leaders across the continents under a collaborative environment and achieve their best potential.

About Dr. Wang

    Dr. Jun Wang is a Vice President of Biology at Shanghai Medicilon, Inc. Prior to Medicilon, Dr. Wang was a Vice President and Head of Biology at Sundia MediTech. Before joining Sundia, Dr. Wang had served at Merck Sharp & Dohme Corp. for about 9 years leading multiple drug-discovery programs on principles of food-animal growth promotion, infectious diseases, diabetics and cardiovascular diseases. Prior to Merck, Dr. Wang worked at a biotech company, Molecumetics, in Seattle as a head of biology and served as an assistant affiliate associate professor in University of Texas Southwestern Medical Center and University of Washington for 5 years. Dr. Wang has published numerous papers as the corresponding author in leading scientific journals (Nature, PNAS, JBC etc). Dr. Wang has been invited by many organizations including University of Cambridge, Royal Society of Chemistry, Naito Foundation etc. for presentations on his discovery of novel candidates of antibiotics (Platensimycin and Platencin). Dr Wang is also acting as an adjunct professor in Fudan University and serving as an editorial board member of five international journals. 

    Dr. Wang got his B.S. in biophysics from Fudan University and received his Ph.D. in the area of molecular biology and biochemistry from Kobe University (Japan). Post-doc training was followed in the Department of Pharmacology at UT Southwestern Medical Center (Dallas).